Nature's Sunshine Products (NATR) 10-Q 9 Aug 17 2017 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Jul. 28, 2017
Document and Entity Information
Entity Registrant Name	NATURES SUNSHINE PRODUCTS INC
Entity Central Index Key	275,053
Document Type	10-Q
Document Period End Date	Jun. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		18,892,781
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 31,821	$ 32,284
Accounts receivable, net of allowance for doubtful accounts of $190 and $205, respectively	9,220	7,738
Investments available for sale	0	1,776
Assets held for sale	0	521
Inventories	50,958	47,597
Prepaid expenses and other	5,902	4,585
Total current assets	97,901	94,501
Property, plant and equipment, net	72,662	73,272
Investment securities - trading	1,786	1,391
Intangible assets, net	1,007	976
Deferred income tax assets	21,391	21,590
Other assets	13,816	13,840
Total assets	208,563	205,570
Current liabilities:
Accounts payable	5,361	5,305
Accrued volume incentives and service fees	17,654	16,264
Accrued liabilities	21,798	24,400
Deferred revenue	5,258	3,672
Revolving credit facility payable	11,954	9,919
Income taxes payable	2,795	3,475
Total current liabilities	64,820	63,035
Liability related to unrecognized tax benefits	6,966	6,755
Deferred compensation payable	1,786	1,391
Other liabilities	1,307	1,991
Total liabilities	74,879	73,172
Commitments and contingencies
Shareholders’ equity:
Common stock, no par value, 50,000 shares authorized, 18,893 and 18,757 shares issued and outstanding, respectively	131,008	129,654
Retained earnings	12,805	12,718
Noncontrolling interests	756	1,286
Accumulated other comprehensive loss	(10,885)	(11,260)
Total shareholders’ equity	133,684	132,398
Total liabilities and shareholders' equity	$ 208,563	$ 205,570

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 190	$ 205
Common stock, par value (in dollars per share)
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares issued (in shares)	18,893,000	18,757,000
Common stock, shares outstanding (in shares)	18,893,000	18,757,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income Statement [Abstract]
Net sales	$ 81,344	$ 89,366	$ 164,442	$ 171,768
Cost of sales	(21,197)	(23,078)	(42,925)	(45,098)
Gross profit	60,147	66,288	121,517	126,670
Operating expenses:
Volume incentives	28,288	30,791	57,271	60,668
Selling, general and administrative	31,836	31,249	62,172	59,634
Operating income	23	4,248	2,074	6,368
Other income (expense), net	441	(622)	1,716	937
Income before provision for income taxes	464	3,626	3,790	7,305
Provision for income taxes	884	1,260	2,347	3,150
Net income (loss)	(420)	2,366	1,443	4,155
Net loss attributable to noncontrolling interests	(233)	(202)	(530)	(482)
Net income (loss) attributable to common shareholders	$ (187)	$ 2,568	$ 1,973	$ 4,637
Basic earnings per share attributable to common shareholders:
Basic earnings (loss) per share attributable to common shareholders (in dollars per share)	$ (0.01)	$ 0.14	$ 0.10	$ 0.25
Diluted earnings per share attributable to common shareholders:
Diluted earnings (loss) per share attributable to common shareholders (in dollars per share)	$ (0.01)	$ 0.14	$ 0.10	$ 0.24
Weighted average basic common shares outstanding (in shares)	18,876	18,723	18,861	18,708
Weighted average diluted common shares outstanding (in shares)	18,876	18,940	19,251	18,946
Dividends declared per common share (in dollars per share)	$ 0	$ 0.10	$ 0.10	$ 0.2

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Statement of Comprehensive Income [Abstract]
Net income	$ (420)	$ 2,366	$ 1,443	$ 4,155
Foreign currency translation gain (net of tax)	(552)	537	360	462
Net unrealized gains on investment securities (net of tax)	15	4	15	16
Total comprehensive income	$ (957)	$ 2,907	$ 1,818	$ 4,633

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY - 6 months ended Jun. 30, 2017 - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Retained Earnings	Noncontrolling Interest	Accumulated Other Comprehensive Income (Loss)
Balance at Dec. 31, 2016	$ 132,398	$ 129,654	$ 12,718	$ 1,286	$ (11,260)
Balance (in shares) at Dec. 31, 2016	18,757	18,757
Increase (Decrease) in Shareholders' Equity
Share-based compensation expense	$ 1,762	$ 1,762
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax	(408)	$ (408)
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax (in shares)		136
Cash dividends ($0.10 per share)	(1,886)		(1,886)
Net income	1,443		1,973	(530)
Other comprehensive income	375				375
Balance at Jun. 30, 2017	$ 133,684	$ 131,008	$ 12,805	$ 756	$ (10,885)
Balance (in shares) at Jun. 30, 2017	18,893	18,893

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical)	6 Months Ended
	Jun. 30, 2017$ / shares
Statement of Stockholders' Equity [Abstract]
Cash dividends (in dollars per share)	$ 0.10

CONDENSED CONSOLIDATED STATEME8

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 1,443	$ 4,155
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Provision for doubtful accounts	(22)	62
Depreciation and amortization	3,585	2,396
Share-based compensation expense	1,762	1,586
(Gain) loss on sale of property and equipment	(10)	78
Deferred income taxes	263	311
Purchase of trading investment securities	(367)	(252)
Proceeds from sale of trading investment securities	73	56
Realized and unrealized gains on investments	(79)	(60)
Foreign exchange gains	(1,882)	(546)
Changes in assets and liabilities:
Accounts receivable	(1,429)	(164)
Inventories	(2,359)	(6,177)
Prepaid expenses and other current assets	(1,221)	(912)
Other assets	358	(1,027)
Accounts payable	109	2,402
Accrued volume incentives and service fees	1,082	2,798
Accrued liabilities	(3,542)	950
Deferred revenue	1,586	735
Income taxes payable	(636)	(150)
Liability related to unrecognized tax benefits	207	231
Deferred compensation payable	395	(9)
Net cash provided by (used in) operating activities	(684)	6,463
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property, plant and equipment	(3,134)	(4,592)
Proceeds from sale of property, plant and equipment	522	0
Proceeds from sale/maturities of investments available for sale	1,776	0
Net cash used in investing activities	(836)	(4,592)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments of cash dividends	(1,886)	(3,756)
Net borrowings on revolving credit facility	2,035	1,224
Net proceeds from the exercise of stock options	104	59
Payment of withholding taxes related to the vesting of restricted stock units	(512)	(169)
Net cash used in financing activities	(259)	(2,642)
Effect of exchange rates on cash and cash equivalents	1,316	779
Net increase (decrease) in cash and cash equivalents	(463)	8
Cash and cash equivalents at the beginning of the period	32,284	41,420
Cash and cash equivalents at the end of the period	31,821	41,428
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for income taxes	2,418	3,036
Cash paid for interest	$ 108	$ 122

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation Nature’s Sunshine Products, Inc., together with its subsidiaries (hereinafter referred to collectively as the “Company”), is a natural health and wellness company primarily engaged in the manufacturing and direct selling of nutritional and personal care products. The Company sells its products to a sales force of independent distributors who use the products themselves or resell them to consumers. Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. The Company consolidates the joint ventures in Hong Kong and China in its consolidated financial statements, with another party's interest presented as noncontrolling interest. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals), considered necessary for a fair presentation of the Company’s financial information as of June 30, 2017 , and for the three and six -month periods ended June 30, 2017 and 2016 . The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the fiscal year ending December 31, 2017 . It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 . Noncontrolling Interests Noncontrolling interests decreased as a result of the net loss attributable to the noncontrolling interests by 0.5 million and $0.5 million during the six months ended June 30, 2017 and 2016 , respectively. As of June 30, 2017 , and December 31, 2016 , noncontrolling interests were 0.8 million and $1.3 million , respectively. Classification of Ukraine as a Highly Inflationary Economy and Devaluation of Its Currency As of June 2017, Ukraine has been designated as a highly inflationary economy. The U.S. dollar is the Company’s functional currency for this market. As a result, there were no resulting gains or losses from a re-measurement of the financial statements using official rates of the Company’s Ukrainian subsidiary. However, as a result of the weakening of the Ukraine Hryvnia, the purchasing power of the Company’s independent Distributors in this market has diminished. During the three months ended June 30, 2017 and 2016 , the Company’s Ukrainian subsidiary’s net sales represented approximately 2.1 percent and 2.0 percent of consolidated net sales, respectively. During the six months ended June 30, 2017 and 2016 , the Company’s Ukrainian subsidiary’s net sales represented approximately 2.4 percent and 2.1 percent of consolidated net sales, respectively. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09 - Revenue from Contracts with Customers (Topic 606), and has subsequently issued ASUs 2015-14 - Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, 2016-08 - Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross Versus Net), 2016-10 - Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, 2016-12 - Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, and 2016-20 - Revenue from Contracts with Customers (Topic 606): Technical Corrections and Improvements to Topic 606 (collectively, Topic 606). Topic 606 outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The guidance is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract. This guidance is effective for the Company beginning on January 1, 2018, and provides the Company with the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. The Company expects to adopt Topic 606 using the modified retrospective approach, under which the cumulative effect of initially applying Topic 606 is recognized as an adjustment to the opening balance of retained earnings in the first quarter of 2018. The Company is concluding the assessment phase of implementing this guidance. The Company has evaluated each of the five steps in Topic 606, which are as follows: 1) Identify the contract with the customer; 2) Identify the performance obligations in the contract; 3) Determine the transaction price; 4) Allocate the transaction price to the performance obligations; and 5) Recognize revenue when (or as) performance obligations are satisfied. The Company expects to identify similar performance obligations under ASC Topic 606, as compared with deliverables and separate units of account previously identified. As a result, the adoption of this ASU is not expected to have a material impact on the Company’s results of operations, consolidated financial statements and footnote disclosures. There are also certain considerations related to internal control over financial reporting that are associated with implementing Topic 606. The Company is currently evaluating its control framework for revenue recognition and identifying any changes that may need to be made in response to the new guidance. Disclosure requirements under the new guidance in Topic 606 have been significantly expanded in comparison to the disclosure requirements under the current guidance. Designing and implementing the appropriate controls over gathering and reporting the information required under Topic 606 is currently in process. In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes. This guidance requires that entities with a classified statement of financial position present all deferred tax assets and liabilities as noncurrent. This update is effective and has been applied on the retrospective basis. Other than the netting of current deferred tax assets of $5.6 million , which increased long-term deferred tax assets from $16.0 million to $21.6 million as of December 31, 2016, the adoption of this ASU did not have a material impact on the Company’s results of operations and consolidated financial statements. In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This update amends the guidance in U.S. Generally Accepted Accounting Principles ("U.S. GAAP") on the classification and measurement of financial instruments. Although the ASU retains many current requirements, it significantly revises an entity’s accounting related to (1) the classification and measurement of investments in equity securities and (2) the presentation of certain fair value changes for financial liabilities measured at fair value. The ASU also amends certain disclosure requirements associated with the fair value of financial instruments. This update is effective for interim and annual periods beginning after December 15, 2017. The adoption of this ASU is not expected to have a material impact on the Company’s results of operations, consolidated financial statements and footnote disclosures. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842): Accounting for Leases. This update specifies that lessees should recognize assets and liabilities arising from all leases, except for leases with a lease term of 12 months or less. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee will largely remain unchanged and shall continue to depend on its classification as a finance or operating lease. The ASU will be effective for annual periods beginning after December 15, 2018 with early adoption permitted. The adoption of this ASU is not expected to have a material impact on the Company’s results of operations; however, it is expected to gross-up the consolidated balance sheet as a result of recognizing a lease asset along with a similar lease liability. In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. This update amends the scope of modification accounting surrounding share-based payment arrangements as issued in ASU 2016-09 by providing guidance on the various types of changes which would trigger modification accounting for share-based payment awards. ASU 2017-09 is effective for annual periods beginning after December 15, 2017, and interim periods within those annual periods. Early adoption is permitted, including adoption in any interim period, for public business entities for reporting periods for which financial statements have not yet been issued. While the Company does not expect the adoption of ASU 2017-09 to have a material effect on its business, the Company is still evaluating any potential impact that adoption of ASU 2017-09 may have on its results of operations, consolidated financial statements and footnote disclosures.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2017
Inventory Disclosure [Abstract]
Inventories	Inventories The composition of inventories is as follows (dollar amounts in thousands): June 30, December 31, Raw materials $ 12,969 $ 14,995 Work in progress 1,141 694 Finished goods 36,848 31,908 Total inventory $ 50,958 $ 47,597

Investments

Investments	6 Months Ended
	Jun. 30, 2017
Investments, Debt and Equity Securities [Abstract]
Investments	Investments As of June 30, 2017, the Company had no investments available for sale. Proceeds from the sale of available-for-sale investments were $1.8 million during the six-month period ended June 30, 2017. The amortized cost and estimated fair values of available-for-sale securities by balance sheet classification are as follows (dollar amounts in thousands): As of December 31, 2016 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value U.S. government securities funds $ 1,799 $ — $ (23 ) $ 1,776 Total short-term investment securities $ 1,799 $ — $ (23 ) $ 1,776 There were no proceeds from the sale of investments during the six -months ended June 30, 2016. The Company’s trading securities portfolio totaled $1.8 million at June 30, 2017 , and $1.4 million at December 31, 2016 , and generated gains of $51,000 and $28,000 for the three months ended and $102,000 and $35,000 for the six months ended June 30, 2017 and 2016 , respectively. As of June 30, 2017 , and December 31, 2016 , the Company had an unrealized loss of $0 and $23,000 , respectively, in its U.S. government securities funds. There were no securities that were in a loss position for more than 12 months.

Revolving Credit Facility

Revolving Credit Facility	6 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Revolving Credit Facility	Revolving Credit Facility The Company had a revolving credit agreement with Wells Fargo Bank, N.A. with a borrowing limit of $25.0 million that was to mature on September 1, 2017, in accordance with its terms (the “Wells Fargo Credit Agreement”). The Company paid interest under the Wells Fargo Credit Agreement at LIBOR plus 1.25 percent ( 2.50 percent as of June 30, 2017 , and 2.13 percent at December 31, 2016 ), and an annual commitment fee of 0.25 percent on the unused portion of the commitment. The Company settled its net borrowings under the Wells Fargo Credit Agreement daily, and as a result, classified its outstanding borrowings as current on its condensed consolidated balance sheet as of June 30, 2017 . At June 30, 2017 , and December 31, 2016 , the outstanding balance under the Wells Fargo Credit Agreement was $12.0 million and $9.9 million , respectively. The Company was in compliance with the debt covenants set forth in the Wells Fargo Credit Agreement as of June 30, 2017 . On July 11, 2017, the Company entered into a revolving credit agreement with Bank of America, N.A with a borrowing limit of $25.0 million that matures on July 11, 2020 (the “Bank of America Credit Agreement”). In connection with the closing of the Bank of America Credit Agreement, the Company terminated the Wells Fargo Credit Agreement and satisfied in full the outstanding balance thereof through borrowings on the Bank of America Credit Agreement. The Company pays interest under the Bank of America Credit Agreement at LIBOR plus 1.25 percent on any borrowings and pays an annual commitment fee of 0.2 percent on the unused portion of the commitment. The Bank of America Credit Agreement contains customary financial covenants, including financial covenants relating to the Company’s solvency, leverage, and minimum EBITDA. In addition, the Bank of America Credit Agreement restricts certain capital expenditures, lease expenditures, other indebtedness, liens on assets, guarantees, loans and advances, dividends, and merger, consolidation and the transfer of assets except as permitted in the Bank of America Credit Agreement. The Bank of America Credit Agreement is collateralized by the Company's manufacturing facility, accounts receivable balance, inventory balance and other assets.

Net Income (Loss) Per Share

Net Income (Loss) Per Share	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Net Income (Loss) Per Share	Net Income (Loss) Per Share Basic net income (loss) per common share (“Basic EPS”), is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per common share (“Diluted EPS”) reflects the potential dilution that could occur if stock options or other contracts to issue common stock were exercised or converted into common stock. The computation of Diluted EPS does not assume exercise or conversion of securities that would have an anti-dilutive effect on net income (loss) per common share. Following is a reconciliation of the numerator and denominator of Basic EPS to the numerator and denominator of Diluted EPS for the three and six months ended June 30, 2017 and 2016 (dollar and share amounts in thousands, except for per share information): Three Months Ended Six Months Ended 2017 2016 2017 2016 Net income (loss) attributable to common shareholders $ (187 ) $ 2,568 $ 1,973 $ 4,637 Basic weighted average shares outstanding 18,876 18,723 18,861 18,708 Basic earnings (loss) per share attributable to common shareholders $ (0.01 ) $ 0.14 $ 0.10 $ 0.25 Diluted shares outstanding Basic weighted-average shares outstanding 18,876 18,723 18,861 18,708 Stock-based awards — 217 390 238 Diluted weighted-average shares outstanding 18,876 18,940 19,251 18,946 Diluted earnings (loss) per share attributable to common shareholders $ (0.01 ) $ 0.14 $ 0.10 $ 0.24 Dilutive shares excluded from diluted-per-share amounts: Stock options — (1) 86 371 86 Anti-dilutive shares excluded from diluted-per-share amounts: Stock options 2,444 (1) 1,445 1,363 1,445 (1) As a result of the net loss for the three months ended June 30, 2017, no potentially dilutive securities are included in the calculation of diluted earnings (loss) per share because such effect would be anti-dilutive. Potentially dilutive securities include 1,540 outstanding options to purchase shares of common stock and 904 restricted stock units. Potentially dilutive shares excluded from diluted-per-share amounts include performance-based options to purchase shares of common stock for which certain earnings metrics have not been achieved. Potentially anti-dilutive shares excluded from diluted-per-share amounts include both (i) non-qualified stock options and unearned performance-based options to purchase shares of common stock with exercise prices greater than the weighted-average share price during the period and (ii) shares that would be anti-dilutive to the computation of diluted net income per share for each of the years presented.

Capital Transactions

Capital Transactions	6 Months Ended
	Jun. 30, 2017
Capital Transactions
Capital Transactions	Capital Transactions Dividends On March 7, 2017, the Company announced a cash dividend of $0.10 per common share in the aggregate of $1.9 million , which was paid on April 3, 2017, to shareholders of record as of March 22, 2017. On May 10, 2017, the Company announced that its Board of Directors elected to suspend the payment of quarterly dividends. The Company's Board of Directors will periodically evaluate the Company’s dividend policy in the future. The declaration of future dividends is subject to the discretion of the Company’s Board of Directors and will depend upon various factors, including the Company’s earnings, financial condition, restrictions imposed by any indebtedness that may be outstanding, cash requirements, future prospects and other factors deemed relevant by the Company's Board of Directors. Share Repurchase Program In November 2014, the Board of Directors authorized a $20.0 million share repurchase program beginning January 1, 2015. Such purchases may be made in the open market, through block trades, in privately negotiated transactions or otherwise. The timing and amount of any shares repurchased will be determined based on the Company’s evaluation of market conditions and other factors and the program may be discontinued or suspended at any time. At June 30, 2017 , the remaining balance available for repurchases under the program was $13.4 million . There were no repurchases of common shares under the share repurchase program by the Company during the six months ended June 30, 2017 and 2016. Share-Based Compensation During the year ended December 31, 2012, the Company’s shareholders adopted and approved the Nature’s Sunshine Products, Inc. 2012 Stock Incentive Plan (the “2012 Incentive Plan”). The 2012 Incentive Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalent rights, performance awards, stock awards and other stock-based awards. The Compensation Committee of the Board of Directors has authority and discretion to determine the type of award, as well as the amount, terms and conditions of each award under the 2012 Incentive Plan, subject to the limitations of the 2012 Incentive Plan. A total of 1,500,000 shares of the Company’s common stock were originally authorized for the granting of awards under the 2012 Incentive Plan. In 2015, the Company’s shareholders approved an amendment to the 2012 Incentive Plan, to increase the number of shares of Common Stock reserved for issuance by 1,500,000 shares. The number of shares available for awards, as well as the terms of outstanding awards, are subject to adjustment as provided in the 2012 Incentive Plan for stock splits, stock dividends, recapitalizations and other similar events. The Company also maintains a stock incentive plan, which was approved by shareholders in 2009 (the “2009 Incentive Plan”). The 2009 Incentive Plan also provided for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalent rights, performance awards, stock awards and other stock-based awards. Under the 2012 Incentive Plan, any shares subject to award, or awards forfeited or reacquired by the Company issued under the 2009 Incentive Plan are available for award up to a maximum of 400,000 shares. Stock Options The Company’s outstanding stock options include time-based stock options, which vest over differing periods of time ranging from the date of issuance to up to 48 months from the option grant date, and performance-based stock options, which have already vested upon achieving operating income margins of six , eight and ten percent as reported in four of five consecutive quarters over the term of the options. Stock option activity for the six -month period ended June 30, 2017 , is as follows (amounts in thousands, except per share information): Number of Shares Weighted Average Exercise Price Per Share Options outstanding at December 31, 2016 1,524 $ 12.41 Granted 25 13.50 Forfeited or canceled — — Exercised (9 ) 11.98 Options outstanding at June 30, 2017 1,540 12.34 During the six months ended June 30, 2017, the Company issued options to purchase 25,000 shares of common stock under the 2012 Stock Incentive Plan to a new member of the Company's Board of Directors. These options were issued with an exercise price of $13.50 per share and a grant date fair value of $4.94 per share, with expected life of five years, risk-free interest rate of 1.8 percent , and expected volatility of 39.8 percent . During the six months ended June 30, 2017, the Company modified vested options to purchase 131,000 shares of common stock for one individual (included in options outstanding above) to extend the expiration date for approximately one year. It is expected the options will terminate by June 30, 2018. This was a modification of the terms of an equity award, and accordingly, the Company treated this as an exchange of the original award for a new award. The Company recorded incremental compensation expense of approximately $0.1 million for the six months ended June 30, 2017, which was included in selling, general and administrative expense on the accompanying statements of operations. Share-based compensation expense from time-based stock options for the three-month periods ended June 30, 2017 and 2016 , was approximately $0.3 million and $0.2 million , respectively. Share-based compensation expense from time-based stock options for the six -month periods ended June 30, 2017 and 2016 , was approximately $0.4 million and $0.4 million , respectively. As of June 30, 2017 and December 31, 2016 , the unrecognized share-based compensation expense related to the grants described above was $0.2 million and $0.3 million , respectively. As of June 30, 2017 , the remaining compensation cost is expected to be recognized over the weighted-average period of approximately 0.6 years . At June 30, 2017 , the aggregate intrinsic value of outstanding stock options to purchase 1,540,000 shares of common stock, exercisable stock options to purchase 1,409,000 shares of common stock and stock options to purchase 130,000 shares of common stock that are expected to vest was $2.2 million , $2.2 million and $0 , respectively. At December 31, 2016 , the aggregate intrinsic value of outstanding options to purchase 1,524,000 shares of common stock, the exercisable options to purchase 1,201,000 shares of common stock, and options to purchase 306,000 shares of common stock expected to vest was $4.2 million , $3.7 million and $0.4 million , respectively. For the six -month periods ended June 30, 2017 and 2016 , the Company issued 9,000 and 25,000 shares of common stock upon the exercise of stock options at an average exercise price of $11.98 and $2.35 per share, respectively. The aggregate intrinsic values of options exercised during the six -month periods ended June 30, 2017 and 2016 , was $7,000 and $0.2 million , respectively. For the six -month period ended June 30, 2017 and 2016 , the Company recognized $0 and $0.1 million of tax benefits from the exercise of stock options during the period, respectively. Restricted Stock Units The Company’s outstanding restricted stock units ("RSUs"), include time-based RSUs, which vest over differing periods of time ranging from 12 months to up to 48 months from the RSU grant date, as well as performance-based RSUs, which vest either upon achieving cumulative annual net sales growth targets over a rolling one-year period or upon achieving earnings-per-share targets over a rolling one-year period. RSUs granted to the Board of Directors contain a restrictive period pursuant to which the shares are not issued until two years after vesting. At June 30, 2017 , and December 31, 2016 , there were 65,000 and 69,000 , respectively, vested RSUs that have been granted to the Board of Directors that have vested but remain subject to the two -year restriction period. RSU activity for the six -month period ended June 30, 2017 , is as follows (amounts in thousands, except per share information): Number of Shares Weighted Average Grant Date Fair Value Restricted Stock Units outstanding at December 31, 2016 838 $ 11.39 Granted 256 12.69 Forfeited (25 ) 12.37 Issued (165 ) 12.16 Restricted Stock Units outstanding at June 30, 2017 904 11.68 During the six -month period ended June 30, 2017 , the Company granted 256,000 RSUs under the 2012 Incentive Plan to the Company’s Board of Directors, executive officers and other employees, which were comprised of both time-based RSUs and net sales and operating income and earnings-per-share performance-based RSUs. The time-based RSUs were issued with a weighted-average grant date fair value of $12.69 per share and vest in annual installments over a three -year period from the grant date or according to the restrictions for the Board of Directors noted above. The net sales and operating income and earnings-per-share performance-based RSUs were issued with a weighted-average grant date fair value of $13.35 per share and vest upon achieving both (i) net sales and operating income targets over a three -year period from the grant date and (ii) earnings-per-share targets over a six -year period from the grant date. RSUs are valued at market value on the date of grant, which is the grant date share price discounted for expected dividend payments during the vesting period. Share-based compensation expense for RSUs for the three-month periods ended June 30, 2017 and 2016 , was approximately $0.7 million and $0.5 million , respectively. Share-based compensation expense from RSUs for the six -month periods ended June 30, 2017 and 2016 , was approximately $1.3 million and $1.1 million , respectively. As of June 30, 2017 , and December 31, 2016 , the unrecognized share-based compensation expense related to the grants described above, excluding incentive awards discussed below, was $2.6 million and $2.0 million , respectively. The remaining compensation expense is expected to be recognized over the weighted average period of approximately 1.2 years . The Company has not recognized any share-based compensation expense related to the net sales and earnings-per-share performance-based RSUs for the six -month periods ended June 30, 2017 and 2016 . Should the Company attain all of the net sales metrics related to the net sales performance-based stock option grants, the Company would recognize up to $4.2 million of potential share-based compensation expense. The number of shares issued upon vesting of RSUs granted pursuant to the Company's share-based compensation plans is net of the minimum statutory withholding requirements that the Company pays on behalf of its employees, which was 20,000 shares for the six -month period ended June 30, 2017 . Although shares withheld are not issued, they are treated as common share repurchases for accounting purposes, as they reduce the number of shares that would have been issued upon vesting. These shares do not count against the authorized capacity under the repurchase program described above.

Segment Information

Segment Information	6 Months Ended
	Jun. 30, 2017
Segment Reporting [Abstract]
Segment Information	Segment Information The Company has four business segments. These business segments are components of the Company for which separate information is available and evaluated regularly by the chief executive officer in deciding how to allocate resources and in assessing relative performance. The Company's four business segments are divided based on the different characteristics of their distributor and customer bases, distributor compensation plans and product formulations, as well as the internal organization of its officers and their responsibilities and business operations. Three business segments operate under the Nature’s Sunshine Products brand (NSP Americas; NSP Russia, Central and Eastern Europe; and China and New Markets), and one business segment operates under the Synergy® WorldWide brand. Reportable business segment information is as follows (dollar amounts in thousands): Three Months Ended Six Months Ended 2017 2016 2017 2016 Net sales: NSP Americas $ 39,421 $ 44,725 $ 84,066 $ 89,908 NSP Russia, Central and Eastern Europe 6,662 6,269 14,269 12,621 Synergy WorldWide 30,363 33,013 57,676 62,861 China and New Markets 4,898 5,359 8,431 6,378 Total net sales 81,344 89,366 164,442 171,768 Contribution margin (1): NSP Americas 16,495 19,103 35,690 38,020 NSP Russia, Central and Eastern Europe 2,246 2,065 4,755 4,246 Synergy WorldWide 9,410 10,245 17,609 19,184 China and New Markets 3,708 4,084 6,192 4,552 Total contribution margin 31,859 35,497 64,246 66,002 Selling, general and administrative expenses (2) 31,836 31,249 62,172 59,634 Operating income 23 4,248 2,074 6,368 Other income (expense), net 441 (622 ) 1,716 937 Income from continuing operations before provision for income taxes $ 464 $ 3,626 $ 3,790 $ 7,305 _________________________________________ (1) Contribution margin consists of net sales less cost of sales and volume incentives expense. (2) Service fees in the China and New Markets segment related to sales in China, occurring after the Company's receipt of its direct selling license, and pre-opening product sales through Hong Kong totaled $1.7 million and $2.6 million for the three and six -month periods ended June 30, 2017 , respectively, compared to $2.0 million for the three and six -month periods ended June 30, 2016 . These service fees are included in the Company's selling, general and administrative expenses. From an individual country perspective, only the United States and South Korea comprise 10 percent or more of consolidated net sales for the three and six -month periods ended June 30, 2017 and 2016 , as follows (dollar amounts in thousands): Three Months Ended Six Months Ended 2017 2016 2017 2016 Net sales: United States $ 33,805 $ 37,598 $ 71,540 $ 75,893 South Korea 12,486 15,473 23,832 28,671 Other 35,053 36,295 69,070 67,204 $ 81,344 $ 89,366 $ 164,442 $ 171,768 Net Sales generated by each of the Company’s product lines is set forth below (dollar amounts in thousands): Three Months Ended Six Months Ended 2017 2016 2017 2016 NSP Americas: General health $ 18,181 $ 20,234 $ 38,047 $ 39,851 Immune 3,169 3,738 8,242 9,314 Cardiovascular 2,820 3,418 6,136 6,530 Digestive 11,660 11,845 23,808 24,924 Personal care 1,487 2,853 3,373 3,783 Weight management 2,104 2,637 4,460 5,506 39,421 44,725 84,066 89,908 NSP Russia, Eastern and Central Europe: General health $ 2,941 $ 2,501 $ 6,499 $ 5,224 Immune 638 857 1,401 1,397 Cardiovascular 480 493 1,011 970 Digestive 2,030 1,407 3,907 3,528 Personal care 424 853 1,032 1,102 Weight management 149 158 419 400 6,662 6,269 14,269 12,621 Synergy WorldWide: General health $ 7,624 $ 9,694 $ 14,311 $ 18,334 Immune 117 41 238 250 Cardiovascular 12,603 13,505 23,706 26,198 Digestive 4,154 3,442 7,619 5,929 Personal care 1,926 1,948 3,993 3,887 Weight management 3,939 4,383 7,809 8,263 30,363 33,013 57,676 62,861 China and New Markets: General health $ 1,085 $ 1,537 $ 1,965 $ 2,008 Immune 120 216 266 347 Cardiovascular 972 1,450 1,553 1,523 Digestive 1,813 1,262 3,455 1,522 Personal care 45 439 121 461 Weight management 863 455 1,071 517 4,898 5,359 8,431 6,378 $ 81,344 $ 89,366 $ 164,442 $ 171,768 From an individual country perspective, only the United States comprised 10 percent or more of consolidated property, plant and equipment as follows (dollar amounts in thousands): June 30, December 31, Property, plant and equipment: United States $ 69,876 $ 70,770 Other 2,786 2,502 Total property, plant and equipment $ 72,662 $ 73,272

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes For the three months ended June 30, 2017 and 2016 , the Company’s provision for income taxes, as a percentage of income before income taxes was 190.5 percent and 34.7 percent , respectively, compared with a U.S. federal statutory rate of 35.0 percent . For the six months ended June 30, 2017 and 2016 , the Company’s provision for income taxes, as a percentage of income before income taxes was 61.9 percent and 43.1 percent , respectively, compared with a U.S. federal statutory rate of 35.0 percent . The difference between the effective tax rate and the U.S. federal statutory tax rate for the three and six months ended June 30, 2017 , was primarily attributed to current year foreign losses, primarily related to China, that presently do not provide future tax benefit, partially offset by foreign tax credit benefits. The difference between the effective tax rate and the U.S. federal statutory tax rate for the three months ended June 30, 2016, was attributed to foreign tax credits arising from intercompany dividends paid by foreign subsidiaries to the U.S. corporation, offset by current year foreign losses, primarily related to China, that presently do not provide future tax benefit, and unfavorable adjustments related to foreign operations. The difference between the effective tax rate and the U.S. federal statutory tax rate for the six months ended June 30, 2016, was attributed to current year foreign losses, primarily related to China, that presently do not provide future tax benefit, and an adjustment of a prior year deferred tax asset related to foreign currency translation amounts, offset partially by foreign tax credits arising from intercompany dividends paid by foreign subsidiaries to the U.S. corporation. Changes to the effective rate due to dividends received from foreign subsidiaries and the impact of foreign tax credits are expected to be recurring. Depending on various factors, changes from the foregoing items may be favorable or unfavorable in a particular period. The Company’s U.S. federal income tax returns for 2013 through 2015 are open to examination for federal tax purposes. The Company has several foreign tax jurisdictions that have open tax years from 2010 through 2016. As of June 30, 2017 , the company had accrued $7.0 million related to unrecognized tax positions, compared with $6.8 million as of December 31, 2016 . This net increase was primarily attributed to changes in contingencies related to international tax. Interim income taxes are based on an estimated annualized effective tax rate applied to the respective quarterly periods, adjusted for discrete tax items in the period in which they occur. Although the Company believes its tax estimates are reasonable, the Company can make no assurance that the final tax outcome of these matters will not be different from that which it has reflected in its historical income tax provisions and accruals. Such differences could have a material impact on the Company’s income tax provision and operating results in the period in which the Company makes such determination.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Legal Proceedings The Company is party to various legal proceedings. Management cannot predict the ultimate outcome of these proceedings, individually or in the aggregate, or their resulting effect on the Company’s business, financial position, results of operations or cash flows as litigation and related matters are subject to inherent uncertainties, and unfavorable rulings could occur. Were an unfavorable outcome to occur, there exists the possibility of a material adverse impact on the business, financial position, results of operations, or cash flows for the period in which the ruling occurs and/or future periods. The Company maintains product liability, general liability and excess liability insurance coverage. However, no assurances can be given that such insurance will continue to be available at an acceptable cost to the Company, that such coverage will be sufficient to cover one or more large claims, or that the insurers will not successfully disclaim coverage as to a pending or future claim. Non-Income Tax Contingencies The Company has reserved for certain state sales and use tax and foreign non-income tax contingencies based on the likelihood of an obligation in accordance with accounting guidance for probable loss contingencies. Loss contingency provisions are recorded for probable losses at management’s best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount is recorded. The Company provides provisions for potential payments of tax to various tax authorities for contingencies related to non-income tax matters, including value-added taxes and sales tax. The Company provides provisions for U.S. state sales taxes in each of the states where the Company has nexus. As of June 30, 2017 and December 31, 2016 , accrued liabilities were $0.3 million , related to non-income tax contingencies. While management believes that the assumptions and estimates used to determine this liability are reasonable, the ultimate outcome of those matters cannot presently be determined. The Company believes future payments related to these matters could range from $0 to approximately $3.8 million . Other Litigation The Company is party to various other legal proceedings in several foreign jurisdictions related to value-added tax assessments and other civil litigation. As of each of June 30, 2017 , and December 31, 2016 , accrued liabilities were $0.7 million related to the estimated outcome of these proceedings. In addition, the Company is party to other litigation where there is a reasonable possibility that a loss may be incurred, either the losses are not considered to be probable or the Company cannot at this time estimate the loss, if any; therefore, no provision for losses has been provided. The Company believes future payments related to these matters could range from $0 to approximately $0.5 million .

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The fair value of a financial instrument is the amount that could be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets are marked to bid prices and financial liabilities are marked to offer prices. Fair value measurements do not include transaction costs. A fair value hierarchy is used to prioritize the quality and reliability of the information used to determine fair values of each financial instrument. Categorization within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. The fair value hierarchy is defined into the following three categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data. The following table presents the Company’s hierarchy for its assets, measured at fair value on a recurring basis, as of June 30, 2017 (dollar amounts in thousands): Level 1 Level 2 Level 3 Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total Trading Investment securities 1,786 — — 1,786 Total assets measured at fair value on a recurring basis $ 1,786 $ — $ — $ 1,786 The following table presents the Company’s hierarchy for its assets, measured at fair value on a recurring basis, as of December 31, 2016 (dollar amounts in thousands): Level 1 Level 2 Level 3 Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total Investments available-for-sale U.S. government security funds $ 1,776 $ — $ — $ 1,776 Trading Investment securities 1,391 — — 1,391 Total assets measured at fair value on a recurring basis $ 3,167 $ — $ — $ 3,167 Investments available-for-sale — The majority of the Company’s investment portfolio consists of U.S. government security funds. The Level 1 securities are valued using quoted prices for identical assets in active markets including equity securities and U.S. government treasuries. Trading Investment securities — The Company’s trading portfolio consists of various marketable securities that are valued using quoted prices in active markets. For the six months ended June 30, 2017 , and for the year ended December 31, 2016 , there were no fair value measurements using significant other observable inputs (Level 2) or significant unobservable inputs (Level 3). The carrying amounts reflected on the condensed consolidated balance sheet for cash and cash equivalents, accounts receivable, accounts payable and the revolving credit facility payable approximate fair value due to their short-term nature. During the six months ended June 30, 2017 and 2016 , the Company did not have any re-measurements of non-financial assets at fair value on a nonrecurring basis subsequent to their initial recognition.

Basis of Presentation (Policies

Basis of Presentation (Policies)	6 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation Nature’s Sunshine Products, Inc., together with its subsidiaries (hereinafter referred to collectively as the “Company”), is a natural health and wellness company primarily engaged in the manufacturing and direct selling of nutritional and personal care products. The Company sells its products to a sales force of independent distributors who use the products themselves or resell them to consumers.
Principles of Consolidation	Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. The Company consolidates the joint ventures in Hong Kong and China in its consolidated financial statements, with another party's interest presented as noncontrolling interest. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals), considered necessary for a fair presentation of the Company’s financial information as of June 30, 2017 , and for the three and six -month periods ended June 30, 2017 and 2016 . The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the fiscal year ending December 31, 2017 . It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 .
Noncontrolling Interest	Noncontrolling Interests Noncontrolling interests decreased as a result of the net loss attributable to the noncontrolling interests by 0.5 million and $0.5 million during the six months ended June 30, 2017 and 2016 , respectively. As of June 30, 2017 , and December 31, 2016 , noncontrolling interests were 0.8 million and $1.3 million , respectively.
Classification of Ukraine as a Highly Inflationary Economy and Devaluation of Its Currency	Classification of Ukraine as a Highly Inflationary Economy and Devaluation of Its Currency As of June 2017, Ukraine has been designated as a highly inflationary economy. The U.S. dollar is the Company’s functional currency for this market. As a result, there were no resulting gains or losses from a re-measurement of the financial statements using official rates of the Company’s Ukrainian subsidiary. However, as a result of the weakening of the Ukraine Hryvnia, the purchasing power of the Company’s independent Distributors in this market has diminished. During the three months ended June 30, 2017 and 2016 , the Company’s Ukrainian subsidiary’s net sales represented approximately 2.1 percent and 2.0 percent of consolidated net sales, respectively. During the six months ended June 30, 2017 and 2016 , the Company’s Ukrainian subsidiary’s net sales represented approximately 2.4 percent and 2.1 percent of consolidated net sales, respectively.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09 - Revenue from Contracts with Customers (Topic 606), and has subsequently issued ASUs 2015-14 - Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, 2016-08 - Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross Versus Net), 2016-10 - Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, 2016-12 - Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, and 2016-20 - Revenue from Contracts with Customers (Topic 606): Technical Corrections and Improvements to Topic 606 (collectively, Topic 606). Topic 606 outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The guidance is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract. This guidance is effective for the Company beginning on January 1, 2018, and provides the Company with the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. The Company expects to adopt Topic 606 using the modified retrospective approach, under which the cumulative effect of initially applying Topic 606 is recognized as an adjustment to the opening balance of retained earnings in the first quarter of 2018. The Company is concluding the assessment phase of implementing this guidance. The Company has evaluated each of the five steps in Topic 606, which are as follows: 1) Identify the contract with the customer; 2) Identify the performance obligations in the contract; 3) Determine the transaction price; 4) Allocate the transaction price to the performance obligations; and 5) Recognize revenue when (or as) performance obligations are satisfied. The Company expects to identify similar performance obligations under ASC Topic 606, as compared with deliverables and separate units of account previously identified. As a result, the adoption of this ASU is not expected to have a material impact on the Company’s results of operations, consolidated financial statements and footnote disclosures. There are also certain considerations related to internal control over financial reporting that are associated with implementing Topic 606. The Company is currently evaluating its control framework for revenue recognition and identifying any changes that may need to be made in response to the new guidance. Disclosure requirements under the new guidance in Topic 606 have been significantly expanded in comparison to the disclosure requirements under the current guidance. Designing and implementing the appropriate controls over gathering and reporting the information required under Topic 606 is currently in process. In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes. This guidance requires that entities with a classified statement of financial position present all deferred tax assets and liabilities as noncurrent. This update is effective and has been applied on the retrospective basis. Other than the netting of current deferred tax assets of $5.6 million , which increased long-term deferred tax assets from $16.0 million to $21.6 million as of December 31, 2016, the adoption of this ASU did not have a material impact on the Company’s results of operations and consolidated financial statements. In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This update amends the guidance in U.S. Generally Accepted Accounting Principles ("U.S. GAAP") on the classification and measurement of financial instruments. Although the ASU retains many current requirements, it significantly revises an entity’s accounting related to (1) the classification and measurement of investments in equity securities and (2) the presentation of certain fair value changes for financial liabilities measured at fair value. The ASU also amends certain disclosure requirements associated with the fair value of financial instruments. This update is effective for interim and annual periods beginning after December 15, 2017. The adoption of this ASU is not expected to have a material impact on the Company’s results of operations, consolidated financial statements and footnote disclosures. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842): Accounting for Leases. This update specifies that lessees should recognize assets and liabilities arising from all leases, except for leases with a lease term of 12 months or less. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee will largely remain unchanged and shall continue to depend on its classification as a finance or operating lease. The ASU will be effective for annual periods beginning after December 15, 2018 with early adoption permitted. The adoption of this ASU is not expected to have a material impact on the Company’s results of operations; however, it is expected to gross-up the consolidated balance sheet as a result of recognizing a lease asset along with a similar lease liability. In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. This update amends the scope of modification accounting surrounding share-based payment arrangements as issued in ASU 2016-09 by providing guidance on the various types of changes which would trigger modification accounting for share-based payment awards. ASU 2017-09 is effective for annual periods beginning after December 15, 2017, and interim periods within those annual periods. Early adoption is permitted, including adoption in any interim period, for public business entities for reporting periods for which financial statements have not yet been issued. While the Company does not expect the adoption of ASU 2017-09 to have a material effect on its business, the Company is still evaluating any potential impact that adoption of ASU 2017-09 may have on its results of operations, consolidated financial statements and footnote disclosures.

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2017
Inventory Disclosure [Abstract]
Schedule of composition of inventories	The composition of inventories is as follows (dollar amounts in thousands): June 30, December 31, Raw materials $ 12,969 $ 14,995 Work in progress 1,141 694 Finished goods 36,848 31,908 Total inventory $ 50,958 $ 47,597

Investments (Tables)

Investments (Tables)	6 Months Ended
	Jun. 30, 2017
Investments, Debt and Equity Securities [Abstract]
Schedule of amortized cost and estimated fair values of available-for-sale securities by balance sheet classification	The amortized cost and estimated fair values of available-for-sale securities by balance sheet classification are as follows (dollar amounts in thousands): As of December 31, 2016 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value U.S. government securities funds $ 1,799 $ — $ (23 ) $ 1,776 Total short-term investment securities $ 1,799 $ — $ (23 ) $ 1,776

Net Income (Loss) Per Share (Ta

Net Income (Loss) Per Share (Tables)	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Schedule of reconciliation of the numerator and denominator of Basic EPS to the numerator and denominator of Diluted EPS	Following is a reconciliation of the numerator and denominator of Basic EPS to the numerator and denominator of Diluted EPS for the three and six months ended June 30, 2017 and 2016 (dollar and share amounts in thousands, except for per share information): Three Months Ended Six Months Ended 2017 2016 2017 2016 Net income (loss) attributable to common shareholders $ (187 ) $ 2,568 $ 1,973 $ 4,637 Basic weighted average shares outstanding 18,876 18,723 18,861 18,708 Basic earnings (loss) per share attributable to common shareholders $ (0.01 ) $ 0.14 $ 0.10 $ 0.25 Diluted shares outstanding Basic weighted-average shares outstanding 18,876 18,723 18,861 18,708 Stock-based awards — 217 390 238 Diluted weighted-average shares outstanding 18,876 18,940 19,251 18,946 Diluted earnings (loss) per share attributable to common shareholders $ (0.01 ) $ 0.14 $ 0.10 $ 0.24 Dilutive shares excluded from diluted-per-share amounts: Stock options — (1) 86 371 86 Anti-dilutive shares excluded from diluted-per-share amounts: Stock options 2,444 (1) 1,445 1,363 1,445

Capital Transactions (Tables)

Capital Transactions (Tables)	6 Months Ended
	Jun. 30, 2017
Capital Transactions
Schedule of stock option activity	Stock option activity for the six -month period ended June 30, 2017 , is as follows (amounts in thousands, except per share information): Number of Shares Weighted Average Exercise Price Per Share Options outstanding at December 31, 2016 1,524 $ 12.41 Granted 25 13.50 Forfeited or canceled — — Exercised (9 ) 11.98 Options outstanding at June 30, 2017 1,540 12.34
Schedule of restricted stock unit activity	RSU activity for the six -month period ended June 30, 2017 , is as follows (amounts in thousands, except per share information): Number of Shares Weighted Average Grant Date Fair Value Restricted Stock Units outstanding at December 31, 2016 838 $ 11.39 Granted 256 12.69 Forfeited (25 ) 12.37 Issued (165 ) 12.16 Restricted Stock Units outstanding at June 30, 2017 904 11.68

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Jun. 30, 2017
Segment Reporting [Abstract]
Schedule of reportable business segment information	Reportable business segment information is as follows (dollar amounts in thousands): Three Months Ended Six Months Ended 2017 2016 2017 2016 Net sales: NSP Americas $ 39,421 $ 44,725 $ 84,066 $ 89,908 NSP Russia, Central and Eastern Europe 6,662 6,269 14,269 12,621 Synergy WorldWide 30,363 33,013 57,676 62,861 China and New Markets 4,898 5,359 8,431 6,378 Total net sales 81,344 89,366 164,442 171,768 Contribution margin (1): NSP Americas 16,495 19,103 35,690 38,020 NSP Russia, Central and Eastern Europe 2,246 2,065 4,755 4,246 Synergy WorldWide 9,410 10,245 17,609 19,184 China and New Markets 3,708 4,084 6,192 4,552 Total contribution margin 31,859 35,497 64,246 66,002 Selling, general and administrative expenses (2) 31,836 31,249 62,172 59,634 Operating income 23 4,248 2,074 6,368 Other income (expense), net 441 (622 ) 1,716 937 Income from continuing operations before provision for income taxes $ 464 $ 3,626 $ 3,790 $ 7,305 _________________________________________ (1) Contribution margin consists of net sales less cost of sales and volume incentives expense. (2) Service fees in the China and New Markets segment related to sales in China, occurring after the Company's receipt of its direct selling license, and pre-opening product sales through Hong Kong totaled $1.7 million and $2.6 million for the three and six -month periods ended June 30, 2017 , respectively, compared to $2.0 million for the three and six -month periods ended June 30, 2016 . These service fees are included in the Company's selling, general and administrative expenses.
Schedule of consolidated net sales revenue by geographical locations	From an individual country perspective, only the United States and South Korea comprise 10 percent or more of consolidated net sales for the three and six -month periods ended June 30, 2017 and 2016 , as follows (dollar amounts in thousands): Three Months Ended Six Months Ended 2017 2016 2017 2016 Net sales: United States $ 33,805 $ 37,598 $ 71,540 $ 75,893 South Korea 12,486 15,473 23,832 28,671 Other 35,053 36,295 69,070 67,204 $ 81,344 $ 89,366 $ 164,442 $ 171,768
Schedule of revenue generated by each of the Company's product lines	Net Sales generated by each of the Company’s product lines is set forth below (dollar amounts in thousands): Three Months Ended Six Months Ended 2017 2016 2017 2016 NSP Americas: General health $ 18,181 $ 20,234 $ 38,047 $ 39,851 Immune 3,169 3,738 8,242 9,314 Cardiovascular 2,820 3,418 6,136 6,530 Digestive 11,660 11,845 23,808 24,924 Personal care 1,487 2,853 3,373 3,783 Weight management 2,104 2,637 4,460 5,506 39,421 44,725 84,066 89,908 NSP Russia, Eastern and Central Europe: General health $ 2,941 $ 2,501 $ 6,499 $ 5,224 Immune 638 857 1,401 1,397 Cardiovascular 480 493 1,011 970 Digestive 2,030 1,407 3,907 3,528 Personal care 424 853 1,032 1,102 Weight management 149 158 419 400 6,662 6,269 14,269 12,621 Synergy WorldWide: General health $ 7,624 $ 9,694 $ 14,311 $ 18,334 Immune 117 41 238 250 Cardiovascular 12,603 13,505 23,706 26,198 Digestive 4,154 3,442 7,619 5,929 Personal care 1,926 1,948 3,993 3,887 Weight management 3,939 4,383 7,809 8,263 30,363 33,013 57,676 62,861 China and New Markets: General health $ 1,085 $ 1,537 $ 1,965 $ 2,008 Immune 120 216 266 347 Cardiovascular 972 1,450 1,553 1,523 Digestive 1,813 1,262 3,455 1,522 Personal care 45 439 121 461 Weight management 863 455 1,071 517 4,898 5,359 8,431 6,378 $ 81,344 $ 89,366 $ 164,442 $ 171,768
Schedule of consolidated property, plant and equipment by geographical locations	From an individual country perspective, only the United States comprised 10 percent or more of consolidated property, plant and equipment as follows (dollar amounts in thousands): June 30, December 31, Property, plant and equipment: United States $ 69,876 $ 70,770 Other 2,786 2,502 Total property, plant and equipment $ 72,662 $ 73,272

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Schedule of the Company's hierarchy for assets measured at fair value on a recurring basis	The following table presents the Company’s hierarchy for its assets, measured at fair value on a recurring basis, as of June 30, 2017 (dollar amounts in thousands): Level 1 Level 2 Level 3 Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total Trading Investment securities 1,786 — — 1,786 Total assets measured at fair value on a recurring basis $ 1,786 $ — $ — $ 1,786 The following table presents the Company’s hierarchy for its assets, measured at fair value on a recurring basis, as of December 31, 2016 (dollar amounts in thousands): Level 1 Level 2 Level 3 Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total Investments available-for-sale U.S. government security funds $ 1,776 $ — $ — $ 1,776 Trading Investment securities 1,391 — — 1,391 Total assets measured at fair value on a recurring basis $ 3,167 $ — $ — $ 3,167

Basis of Presentation (Details)

Basis of Presentation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Noncontrolling Interest [Line Items]
Net income (loss)	$ (420)	$ 2,366	$ 1,443	$ 4,155
Total shareholders’ equity	$ 133,684		$ 133,684		$ 132,398
Noncurrent deferred tax assets					21,600
Accounting Standards Update 2015-07
Noncontrolling Interest [Line Items]
Current deferred tax assets					(5,600)
Previously Reported
Noncontrolling Interest [Line Items]
Noncurrent deferred tax assets					16,000
Ukraine
Noncontrolling Interest [Line Items]
Net sales as a percentage of revenue (as a percentage)	210.00%	200.00%	240.00%	210.00%
Noncontrolling Interest
Noncontrolling Interest [Line Items]
Net income (loss)			$ (530)	$ (500)
Total shareholders’ equity	$ 756		$ 756		$ 1,286

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 12,969	$ 14,995
Work in progress	1,141	694
Finished goods	36,848	31,908
Total inventory	$ 50,958	$ 47,597

Investments - Narrative (Detail

Investments - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Proceeds from the sales of available-for-sale securities			$ 1,800,000	$ 0
Trading securities portfolio	$ 1,786,000		1,786,000		$ 1,391,000
Gains on trading securities	51,000	$ 28,000	102,000	$ 35,000
Gross unrealized losses					(23,000)
Securities in a loss position for more than 12 months			0		0
U.S. government security funds
Schedule of Available-for-sale Securities [Line Items]
Gross unrealized losses	$ 0		$ 0		$ (23,000)

Investments - Amortized Cost an

Investments - Amortized Cost and Estimated Fair Values of AFS Securities (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		$ 1,799,000
Gross Unrealized Gains		0
Gross Unrealized Losses		(23,000)
Fair Value		1,776,000
U.S. government security funds
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		1,799,000
Gross Unrealized Gains		0
Gross Unrealized Losses	$ 0	(23,000)
Fair Value		$ 1,776,000

Revolving Credit Facility (Deta

Revolving Credit Facility (Details) - Revolving credit agreement - USD ($)	Jul. 11, 2017	Jun. 30, 2017	Dec. 31, 2016
Wells Fargo Credit Agreement
Long-term debt
Maximum borrowing capacity		$ 25,000,000
Annual commitment fee		0.25%
Long-term debt less current installments		$ 12,000,000	$ 9,900,000
Bank of America Credit Agreement | Subsequent Event
Long-term debt
Maximum borrowing capacity	$ 25,000,000
Margin on variable rate	1.25%
Annual commitment fee	0.20%
LIBOR | Wells Fargo Credit Agreement
Long-term debt
Margin on variable rate		1.25%
Effective interest rate		2.50%	2.13%

Net Income (Loss) Per Share (De

Net Income (Loss) Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Net income (loss) attributable to common shareholders:
Net income (loss) attributable to common shareholders	$ (187)	$ 2,568	$ 1,973	$ 4,637
Basic weighted-average shares outstanding (in shares)	18,876,000	18,723,000	18,861,000	18,708,000
Basic earnings (loss) per share attributable to common shareholders:
Basic earnings (loss) per share attributable to common shareholders (in dollars per share)	$ (0.01)	$ 0.14	$ 0.10	$ 0.25
Diluted shares outstanding
Basic weighted-average shares outstanding (in shares)	18,876,000	18,723,000	18,861,000	18,708,000
Stock-based awards (in shares)	0	217,000	390,000	238,000
Diluted weighted-average shares outstanding (in shares)	18,876,000	18,940,000	19,251,000	18,946,000
Diluted earnings (loss) per share attributable to common shareholders:
Diluted earnings (loss) per share attributable to common shareholders (in dollars per share)	$ (0.01)	$ 0.14	$ 0.10	$ 0.24
Dilutive shares excluded from diluted-per-share amounts:
Stock options (in shares)		86,000	371,000	86,000
Anti-dilutive shares excluded from diluted-per-share amounts:
Stock options (in shares)	2,444,000	1,445,000	1,363,000	1,445,000
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities (in shares)	1,540		1,540
RSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities (in shares)	904		904

Capital Transactions - Addition

Capital Transactions - Additional Information (Details) - USD ($)	Mar. 07, 2017	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Dec. 31, 2015	Nov. 30, 2014	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividends declared per common share (in dollars per share)	$ 0.10	$ 0	$ 0.10	$ 0.10	$ 0.2
Cash dividends declared	$ 1,900,000			$ 1,886,000
Weighted Average Exercise Price Per Share
Granted (in dollars per share)				$ 13.50
Stock options
Number of shares
Options outstanding at the beginning of the period (in shares)				1,524,000
Granted (in shares)				25,000
Forfeited or canceled (in shares)				0
Exercised (in shares)				(9,000)	(25,000)
Options outstanding at the end of the period (in shares)		1,540,000		1,540,000		1,524,000
Weighted Average Exercise Price Per Share
Options outstanding at the beginning of the period (in dollars per share)				$ 12.41
Forfeited or canceled (in dollars per share)				0
Exercised (in dollars per share)				11.98	$ 2.35
Options outstanding at the end of the period (in dollars per share)		$ 12.34		$ 12.34		$ 12.41
Exercisable (in shares)		1,409,000		1,409,000		1,201,000
Expected to vest (in shares)		130,000		130,000		306,000
Aggregate Intrinsic value, outstanding		$ 2,200,000		$ 2,200,000		$ 4,200,000
Aggregate Intrinsic value, exercisable		2,200,000		2,200,000		3,700,000
Aggregate intrinsic values of options exercised				0	$ 200,000
Aggregate Intrinsic value, expected to vest		0		0		386,000
Tax benefit from the exercise of stock options				0	100,000
Time-based stock options
Weighted Average Exercise Price Per Share
Share-based compensation expense		300,000	$ 200,000	400,000	400,000
Unrecognized share-based compensation expense		$ 200,000		$ 200,000		$ 300,000
Weighted-average period over which the remaining compensation cost is expected to be recognized				7 months
Time-based stock options | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period				48 months
Performance based stock options operating income margins
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Operating income margin, one (as a percent)				6.00%
Operating income margin, two (as a percent)				8.00%
Operating income margin, three (as a percent)				10.00%
Performance based stock options sales
Weighted Average Exercise Price Per Share
Share-based compensation expense				$ 0	$ 0
2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized under the plan									1,500,000
Additional number of shares authorized under the plan							1,500,000
Weighted Average Exercise Price Per Share
Exercised (in dollars per share)				$ 13.50
Exercisable (in shares)		25,000		25,000
Share-based compensation, additional disclosures
Weighted-average grant date fair value (in dollars per share)				$ 4.94
Expected contractual life (in years)				5 years
Risk-free interest rate (as a percent)				1.75%
Expected volatility (as a percent)				39.80%
Modification Plan
Weighted Average Exercise Price Per Share
Expected to vest (in shares)		131,000		131,000
Exercisable options, additional term				1 year
Incremental compensation expense				$ 100,000
2009 Incentive Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized under the plan		400,000		400,000
2014 Share Repurchase Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock repurchase program, authorized amount								$ 20,000,000
Remaining balance available for repurchases		$ 13,400,000		$ 13,400,000
Repurchase of common stock (in shares)				0		0

Capital Transactions - Restrict

Capital Transactions - Restricted Stock Units (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
RSUs
Share-based compensation, additional disclosures
Share-based compensation expense	$ 700,000	$ 500,000	$ 1,300,000	$ 1,100,000
Unrecognized share-based compensation expense	2,600,000		$ 2,600,000		$ 2,000,000
Weighted-average period over which the remaining compensation expense is expected to be recognized			1 year 2 months
Minimum statutory withholding requirement paid on behalf of employees (in shares)			20,000
Performance-based RSUs
Share-based compensation, additional disclosures
Share-based compensation expense			$ 0	$ 0
Performance-based RSUs | Maximum
Share-based compensation, additional disclosures
Potential compensation expense	$ 4,200,000		$ 4,200,000
2012 Stock Incentive Plan
Share-based compensation, additional disclosures
Weighted-average grant date fair value (in dollars per share)			$ 4.94
2012 Stock Incentive Plan | RSUs
Number of Shares
Units outstanding at the beginning of the period (in shares)			838,000
Granted (in shares)			256,000
Issued (in shares)			(25,000)
Forfeited (in shares)			(165,000)
Units outstanding at the end of the period (in shares)	904,000		904,000
Weighted Average Grant Date Fair Value
Units outstanding at the beginning of the period (in dollars per share)			$ 11.39
Granted (in dollars per share)			12.69
Issued (in dollars per share)			12.37
Forfeited (in dollars per share)			12.16
Units outstanding at the end of the period (in dollars per share)	$ 11.68		$ 11.68
2012 Stock Incentive Plan | RSUs | Minimum
Share-based compensation, additional disclosures
Vesting period			12 months
2012 Stock Incentive Plan | RSUs | Maximum
Share-based compensation, additional disclosures
Vesting period			48 months
2012 Stock Incentive Plan | RSUs | Board of Directors
Share-based compensation, additional disclosures
Restriction period			2 years
Number of shares subject to restriction period	65,000		65,000		69,000
2012 Stock Incentive Plan | Performance-based RSUs
Share-based compensation, additional disclosures
Weighted-average grant date fair value (in dollars per share)			$ 13.35
2012 Stock Incentive Plan | Time-based RSUs
Share-based compensation, additional disclosures
Vesting period			3 years
Weighted-average grant date fair value (in dollars per share)			$ 12.69
2012 Stock Incentive Plan | Net Sales and Operating Income Targets | Performance-based RSUs
Share-based compensation, additional disclosures
Vesting period			3 years
2012 Stock Incentive Plan | Earnings Per Share Targets | Performance-based RSUs
Share-based compensation, additional disclosures
Vesting period			6 years

Segment Information (Details)

Segment Information (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2017USD ($)segment	Jun. 30, 2016USD ($)	Dec. 31, 2016USD ($)
Segment information
Number of business segments | segment			4
Number of operating segments | segment			3
Net sales revenue:
Total net sales revenue	$ 81,344	$ 89,366	$ 164,442	$ 171,768
Contribution margin:
Total contribution margin	31,859	35,497	64,246	66,002
Selling, general and administrative	31,836	31,249	62,172	59,634
Operating income	23	4,248	2,074	6,368
Other income (expense), net	441	(622)	1,716	937
Income from continuing operations before provision for income taxes	464	3,626	3,790	7,305
Property, plant and equipment
Total property, plant and equipment	72,662		72,662		$ 73,272
United States
Net sales revenue:
Total net sales revenue	33,805	37,598	71,540	75,893
Property, plant and equipment
Total property, plant and equipment	69,876		69,876		70,770
South Korea (Synergy)
Net sales revenue:
Total net sales revenue	12,486	15,473	23,832	28,671
Other
Net sales revenue:
Total net sales revenue	35,053	36,295	69,070	67,204
Property, plant and equipment
Total property, plant and equipment	2,786		2,786		$ 2,502
NSP Americas
Net sales revenue:
Total net sales revenue	39,421	44,725	84,066	89,908
Contribution margin:
Total contribution margin	16,495	19,103	35,690	38,020
NSP Americas | General health
Net sales revenue:
Total net sales revenue	18,181	20,234	38,047	39,851
NSP Americas | Immune
Net sales revenue:
Total net sales revenue	3,169	3,738	8,242	9,314
NSP Americas | Cardiovascular
Net sales revenue:
Total net sales revenue	2,820	3,418	6,136	6,530
NSP Americas | Digestive
Net sales revenue:
Total net sales revenue	11,660	11,845	23,808	24,924
NSP Americas | Personal care
Net sales revenue:
Total net sales revenue	1,487	2,853	3,373	3,783
NSP Americas | Weight management
Net sales revenue:
Total net sales revenue	2,104	2,637	4,460	5,506
NSP Russia, Central and Eastern Europe
Net sales revenue:
Total net sales revenue	6,662	6,269	14,269	12,621
Contribution margin:
Total contribution margin	2,246	2,065	4,755	4,246
NSP Russia, Central and Eastern Europe | General health
Net sales revenue:
Total net sales revenue	2,941	2,501	6,499	5,224
NSP Russia, Central and Eastern Europe | Immune
Net sales revenue:
Total net sales revenue	638	857	1,401	1,397
NSP Russia, Central and Eastern Europe | Cardiovascular
Net sales revenue:
Total net sales revenue	480	493	1,011	970
NSP Russia, Central and Eastern Europe | Digestive
Net sales revenue:
Total net sales revenue	2,030	1,407	3,907	3,528
NSP Russia, Central and Eastern Europe | Personal care
Net sales revenue:
Total net sales revenue	424	853	1,032	1,102
NSP Russia, Central and Eastern Europe | Weight management
Net sales revenue:
Total net sales revenue	149	158	419	400
Synergy WorldWide
Net sales revenue:
Total net sales revenue	30,363	33,013	57,676	62,861
Contribution margin:
Total contribution margin	9,410	10,245	17,609	19,184
Synergy WorldWide | General health
Net sales revenue:
Total net sales revenue	7,624	9,694	14,311	18,334
Synergy WorldWide | Immune
Net sales revenue:
Total net sales revenue	117	41	238	250
Synergy WorldWide | Cardiovascular
Net sales revenue:
Total net sales revenue	12,603	13,505	23,706	26,198
Synergy WorldWide | Digestive
Net sales revenue:
Total net sales revenue	4,154	3,442	7,619	5,929
Synergy WorldWide | Personal care
Net sales revenue:
Total net sales revenue	1,926	1,948	3,993	3,887
Synergy WorldWide | Weight management
Net sales revenue:
Total net sales revenue	3,939	4,383	7,809	8,263
China and New Markets
Net sales revenue:
Total net sales revenue	4,898	5,359	8,431	6,378
Contribution margin:
Total contribution margin	3,708	4,084	6,192	4,552
China and New Markets | General health
Net sales revenue:
Total net sales revenue	1,085	1,537	1,965	2,008
China and New Markets | Immune
Net sales revenue:
Total net sales revenue	120	216	266	347
China and New Markets | Cardiovascular
Net sales revenue:
Total net sales revenue	972	1,450	1,553	1,523
China and New Markets | Digestive
Net sales revenue:
Total net sales revenue	1,813	1,262	3,455	1,522
China and New Markets | Personal care
Net sales revenue:
Total net sales revenue	45	439	121	461
China and New Markets | Weight management
Net sales revenue:
Total net sales revenue	863	455	1,071	517
China and New Markets | Hong Kong
Contribution margin:
Selling, general and administrative	$ 1,700	$ 2,000	$ 2,600	$ 2,000

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Provision (benefit) for income taxes, as a percentage of income before income taxes	190.50%	34.70%	61.90%	43.10%
Statutory U.S. federal income tax rate	35.00%	35.00%	35.00%	35.00%
Liability related to unrecognized tax benefits	$ 6,966		$ 6,966		$ 6,755

Commitments and Contingencies (

Commitments and Contingencies (Details)	6 Months Ended
	Jun. 30, 2017USD ($)claim	Dec. 31, 2016USD ($)
Value-added tax assessments and other civil litigation
Commitments and contingencies
Minimum number of claims that the Company's insurance coverage may not be sufficient to cover | claim	1
Provision for losses	$ 0
Non-Income Tax Contingencies
Commitments and contingencies
Accrued liabilities	300,000	$ 300,000
Minimum | Value-added tax assessments and other civil litigation
Commitments and contingencies
Estimate of possible loss	0
Minimum | Non-Income Tax Contingencies
Commitments and contingencies
Estimate of possible loss	0
Maximum | Value-added tax assessments and other civil litigation
Commitments and contingencies
Estimate of possible loss	500,000
Maximum | Non-Income Tax Contingencies
Commitments and contingencies
Estimate of possible loss	3,800,000
Pending Litigation
Commitments and contingencies
Accrued liabilities	$ 700,000	$ 700,000

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Fair value
Investments available-for-sale		$ 1,776
U.S. government security funds
Fair value
Investments available-for-sale		1,776
Recurring basis | Total
Fair value
Trading investment securities	$ 1,786	1,391
Total assets measured at fair value on a recurring basis	1,786	3,167
Recurring basis | Total | U.S. government security funds
Fair value
Investments available-for-sale		1,776
Recurring basis | Level 1 - Quoted Prices in Active Markets for Identical Assets
Fair value
Trading investment securities	1,786	1,391
Total assets measured at fair value on a recurring basis	1,786	3,167
Recurring basis | Level 1 - Quoted Prices in Active Markets for Identical Assets | U.S. government security funds
Fair value
Investments available-for-sale		1,776
Recurring basis | Level 2 - Significant Other Observable Inputs
Fair value
Trading investment securities	0	0
Total assets measured at fair value on a recurring basis	0	0
Recurring basis | Level 2 - Significant Other Observable Inputs | U.S. government security funds
Fair value
Investments available-for-sale		0
Recurring basis | Level 3 - Significant Unobservable Inputs
Fair value
Trading investment securities	0	0
Total assets measured at fair value on a recurring basis	$ 0	0
Recurring basis | Level 3 - Significant Unobservable Inputs | U.S. government security funds
Fair value
Investments available-for-sale		$ 0